To investigate that a 6-month treatment with avocado soybean unsaponifiable (Piascledine 300 mg) once daily is as effective as with chondroitin sulfate 400 mg three times daily in femorotibial gonarthrosis, and also the carry-over effect for two more months is comparable. Patients were randomized (1:1) to the treatment groups. They received for 6 months 3 capsules chondroitin sulfate per day or one capsule of avocado soybean unsaponifiable (ASU) in a double-dummy technique. A 2-month post-treatment period followed to determine the carry-over effect. Primary efficacy criterion was the change of the WOMAC-index from study begin to end of treatment. Secondary criteria were the changes in Lequesne-index, pain on active movement and at rest, global assessment of efficacy. Three hundred sixty-four patients have been taken up into the trial. Three hundred sixty one patients were eligible for evaluation. One hundred eighty three received ASU 300 mg once daily, one hundred seventy eight chondroitin sulfate three times daily. The WOMAC-index decreased in both groups for approx. 50% to the end of therapy. During the post-treatment observation there was a further slight improvement. There was no statistical significant difference between the treatment groups during the entire observation. All other observed parameters showed the same pattern. The daily intake of rescue medication was reduced continuously. Overall efficacy has been rated excellent and good in more than 80% of the patients in both groups. Both drugs were safe and well tolerated. The first direct comparison between avocado soybean unsaponifiable 300 mg once daily and chondroitin sulfate three times daily reveiled no difference in efficacy or safety aspects between 1 capsule ASU 300 mg per day and 3 capsules chondroitin sulfate per day. It can be assumed that the once daily intake of ASU will lead to a better compliance in routine therapy.

Institute of Rheumatology Charles University Prague Prague Czech Republic

Clin Rheumatol. 2010 Jul;29(7):819-20 PubMed

Zobrazit více v PubMed

Osteoarthritis Cartilage. 1999 Jan;7(1):95-109 PubMed

J Rheumatol. 1997 Apr;24(4):799-802 PubMed

Rheumatology (Oxford). 2004 Mar;43(3):381-4 PubMed

J Rheumatol. 1988 Dec;15(12):1833-40 PubMed

Arthritis Rheum. 1999 Jan;42(1):148-56 PubMed

Arthritis Rheum. 1986 Aug;29(8):1039-49 PubMed

Ann Rheum Dis. 2003 Dec;62(12):1145-55 PubMed

BMC Musculoskelet Disord. 2008 Dec 16;9:165 PubMed

Clin Rheumatol. 2003 Sep;22(3):181-8 PubMed

Osteoarthritis Cartilage. 2008 Apr;16(4):399-408 PubMed

Rev Rhum Mal Osteoartic. 1991 Apr;58(4):241-5 PubMed

J Rheumatol. 2006 Aug;33(8):1668-78 PubMed

J Rheumatol. 2000 Jan;27(1):205-11 PubMed

J Rheumatol. 1997 Feb;24(2):358-64 PubMed

Osteoarthritis Cartilage. 1996 Dec;4(4):217-43 PubMed

Osteoarthritis Cartilage. 2008 Feb;16(2):137-62 PubMed

Rev Rhum Mal Osteoartic. 1989 Feb;56(2):207-11 PubMed

Arthritis Rheum. 2002 Feb;47(1):50-8 PubMed

Scand J Rheumatol Suppl. 1987;65:85-9 PubMed

Scand J Rheumatol. 2001;30(4):242-7 PubMed

Rev Rhum Ed Fr. 1994 Feb;61(2):75-9 PubMed

Osteoarthritis Cartilage. 2008 Mar;16(3):373-84 PubMed

Arch Intern Med. 2002 Oct 14;162(18):2113-23 PubMed

Arthritis Rheum. 2006 May;54(5):1529-35 PubMed

Ann Rheum Dis. 1996 Aug;55(8):552-7 PubMed

Clin Rheumatol. 1998;17(1):31-9 PubMed

Ann Rheum Dis. 2000 Dec;59(12):936-44 PubMed

J Rheumatol. 1996 Aug;23(8):1385-91 PubMed

Arthritis Res Ther. 2009;11(2):R41 PubMed

J Rheumatol. 2003 Aug;30(8):1825-34 PubMed

Ann Rheum Dis. 1957 Dec;16(4):494-502 PubMed

Arch Intern Med. 2006 Sep 25;166(17):1899-906 PubMed

Arthritis Rheum. 1998 Jan;41(1):81-91 PubMed

Osteoarthritis Cartilage. 2003 Feb;11(2):133-40 PubMed

Phys Ther. 2007 Dec;87(12):1716-27 PubMed

Lancet. 1974 Nov 9;2(7889):1127-31 PubMed

Ann Rheum Dis. 2005 Jan;64(1):29-33 PubMed

Clin Exp Rheumatol. 2008 Jul-Aug;26(4):554-60 PubMed

Ann Intern Med. 2007 Apr 17;146(8):580-90 PubMed

J Rheumatol. 2001 Jan;28(1):173-81 PubMed

Rev Rhum Engl Ed. 1997 Dec;64(12):825-34 PubMed